Autolus Therapeutics plc ADR (NASDAQ: AUTL) is -12.34% lower on its value in year-to-date trading and has touched a low of $1.68 and a high of $6.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AUTL stock was last observed hovering at around $1.83 in the last trading session, with the day’s gains setting it 0.23%.
Currently trading at $2.06, the stock is 6.82% and -4.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.38 million and changing 12.57% at the moment leaves the stock -39.53% off its SMA200. AUTL registered -66.93% loss for a year compared to 6-month loss of -47.58%.
The stock witnessed a -2.37% gain in the last 1 month and extending the period to 3 months gives it a -37.95%, and is 13.19% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.36% over the week and 6.03% over the month.
Autolus Therapeutics plc ADR (AUTL) has around 463 employees, a market worth around $548.21M and $10.09M in sales. Profit margin for the company is -2677.90%. Distance from 52-week low is 22.62% and -68.91% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.89%).
with sales reaching $2.98M over the same period.The EPS is expected to grow by 24.89% this year, but quarterly earnings will post 920.38% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
The shares outstanding are 266.12M, and float is at 240.31M with Short Float at 3.95%.
The top institutional shareholder in the company is SYNCONA PORTFOLIO LTD with over 21.35 million shares valued at $74.29 million. The investor’s holdings represent 8.0243 of the AUTL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKSTONE INC. with 20.49 million shares valued at $71.29 million to account for 7.7006 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 17.89 million shares representing 6.7248 and valued at over $62.26 million, while DEEP TRACK CAPITAL, LP holds 5.7409 of the shares totaling 15.27 million with a market value of $53.15 million.
Autolus Therapeutics plc ADR (AUTL): Who are the competitors?
One of the company’s main competitors (and peers) include Novartis AG (NOVN) that is trading 9.82% up over the past 12 months.Bristol Myers Squibb Co. (BMY) lies in the list of competitors of the Autolus Therapeutics plc ADR and is 12.06% higher over the same period from AUTLGilead Sciences Inc. (GILD) is 58.94% up on the 1-year trading charts.
